On Monday, veteran market strategist Sumeet Bagadia highlighted three equities that he believes can outperform as the Nifty 50 hovers around the 22,500 mark. The picks – Axis Bank, Dr Reddy’s Laboratories and Indus Towers – span banking, pharmaceuticals and telecom infrastructure, sectors that have shown resilience amid modest economic data and a stable monetary policy stance. Bagadia set a buying range of ₹800‑₹860 for Axis Bank, targeting ₹950 with a stop‑loss at ₹770, citing improving asset quality and a rebound in loan growth.
For Dr Reddy’s Labs he recommends entering between ₹4,200‑₹4,500, aiming for ₹5,200 and protecting the downside at ₹3,900, pointing to strong pipeline progress and favourable export demand. Indus Towers is suggested at ₹1,050‑₹1,120, with a target of ₹1,350 and a stop‑loss near ₹980, as the company benefits from the rollout of 5G and higher tower utilisation rates. For the average Indian investor, the recommendations offer a blend of growth and defensive traits.
While the upside potential aligns with the broader bullish sentiment in the banking and infrastructure segments, the defined stop‑loss levels provide a risk‑management framework. Investors should consider portfolio diversification, monitor earnings releases and stay aware of any policy shifts that could affect credit costs or foreign exchange, which remain key drivers for these stocks.